Skip to main content

Bayer (0P6S) Receives a Buy from Barclays

Tipranks - Tipranks - Fri Feb 6, 10:26AM CST

In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on Bayer, with a price target of €50.00.

Claim 50% Off TipRanks Premium

Pitman CFA covers the Healthcare sector, focusing on stocks such as UCB SA, Lonza Group Ltd, and Ipsen. According to TipRanks, Pitman CFA has an average return of 16.2% and a 68.53% success rate on recommended stocks.

In addition to Barclays, Bayer also received a Buy from Goldman Sachs’s James Quigley in a report issued on February 2. However, on February 3, TipRanks – Google reiterated a Hold rating on Bayer (LSE: 0P6S).

See the top stocks recommended by analysts >>

Based on Bayer’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of €9.66 billion and a GAAP net loss of €963 million. In comparison, last year the company earned a revenue of €9.97 billion and had a GAAP net loss of €4.18 billion

Read More on GB:0P6S:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).